Some drugmakers are responding to industrywide generics pricing pressure by bulking up via M&A, but not Novartis.
The Swiss company’s Sandoz unit plans to scale back or nix production of some generic drugs, and as a result, it’ll close a 450-employee plant in Broomfield, Colorado, a Novartis spokesman said. The plant will shutter over the next two years, and Novartis will consolidate the production of drug ingredients at a plant in Wilson, North Carolina.
“Novartis is currently experiencing above-average pricing pressure in our U.S. portfolio. With several products no longer competitive in saturated markets, we have made the decision to discontinue or divest these limited growth products to optimize our product portfolio,” the spokesman said via email.
As buyers have consolidated in recent years, they’ve put a price squeeze on copycat drugmakers, spurring double-digit price declines across the industry. And Sandoz isn’t the only company whose manufacturing has taken a hit as a result. In August, Teva—the world’s generics leader—said it would close a whopping 15 plants over the next two years to cut costs.
But that’s not to say Novartis is making cuts across the board. On the contrary, it’s funneled investment and jobs into its manufacturing ops in biologics, an area it’s tabbed for growth.
Back in May, the company said it would add 40 or so jobs to a production site in Morris Plains, New Jersey. That facility focuses on the processes needed to produce Novartis’ CAR-T immuno-oncology treatment, the $475,000 Kymriah, which won FDA approval in late August. And the week before the Morris Plains announcement, the drugmaker said it would add about 350 jobs in Switzerland, mostly in “innovative biologics manufacturing” and development.
Meanwhile, other drugmakers have dealt with the hit to traditional, small-molecule generics by bolstering their portfolios—an option Novartis reportedly looked at last November as it weighed a rumored $8 billion deal for Amneal. That drugmaker instead went to California’s Impax Labs in a pickup unveiled on Tuesday.
By Carly Helfand
Source: Fierce Pharma
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).